These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12672237)

  • 1. Theoretical studies on the inhibition mechanism of cyclooxygenase-2. Is there a unique recognition site?
    Soliva R; Almansa C; Kalko SG; Luque FJ; Orozco M
    J Med Chem; 2003 Apr; 46(8):1372-82. PubMed ID: 12672237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.
    Weber A; Casini A; Heine A; Kuhn D; Supuran CT; Scozzafava A; Klebe G
    J Med Chem; 2004 Jan; 47(3):550-7. PubMed ID: 14736236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors.
    Praveen Rao PN; Amini M; Li H; Habeeb AG; Knaus EE
    J Med Chem; 2003 Nov; 46(23):4872-82. PubMed ID: 14584938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of the dynamic mechanism of ligand binding to cyclooxygenase.
    Llorens O; Perez JJ; Palomer A; Mauleon D
    Bioorg Med Chem Lett; 1999 Oct; 9(19):2779-84. PubMed ID: 10522690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical pharmacology of selective inhibitors of cyclooxygenase-2].
    Patrignani P
    Acta Otorhinolaryngol Ital; 2003 Aug; 23(4 Suppl 74):13-8, 37-40. PubMed ID: 15058604
    [No Abstract]   [Full Text] [Related]  

  • 6. The structure of mammalian cyclooxygenases.
    Garavito RM; Mulichak AM
    Annu Rev Biophys Biomol Struct; 2003; 32():183-206. PubMed ID: 12574066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and cyclooxygenase-2 inhibiting property of 1,5-diarylpyrazoles with substituted benzenesulfonamide moiety as pharmacophore: Preparation of sodium salt for injectable formulation.
    Pal M; Madan M; Padakanti S; Pattabiraman VR; Kalleda S; Vanguri A; Mullangi R; Mamidi NV; Casturi SR; Malde A; Gopalakrishnan B; Yeleswarapu KR
    J Med Chem; 2003 Sep; 46(19):3975-84. PubMed ID: 12954051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring QSAR with E-state index: selectivity requirements for COX-2 versus COX-1 binding of terphenyl methyl sulfones and sulfonamides.
    Chakraborty S; Sengupta C; Roy K
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4665-70. PubMed ID: 15324885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for the observed COX-2/COX-1 selectivity of celecoxib from Monte Carlo simulations.
    Price ML; Jorgensen WL
    Bioorg Med Chem Lett; 2001 Jun; 11(12):1541-4. PubMed ID: 11412976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulfonamido, azidosulfonyl and N-acetylsulfonamido analogues of rofecoxib: 4-[4-(N-acetylsulfonamido)phenyl]-3-(4-methanesulfonylphenyl)-2(5H)furanone is a potent and selective cyclooxygenase-2 inhibitor.
    Zarghi A; Praveen Rao PN; Knaus EE
    Bioorg Med Chem Lett; 2004 Apr; 14(8):1957-60. PubMed ID: 15050636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recognition of cyclooxygenase-2 (COX-2) active site by NSAIDs: a computer modelling study.
    Kothekar V; Sahi S; Srinivasan M; Mohan A; Mishra J
    Indian J Biochem Biophys; 2001; 38(1-2):56-63. PubMed ID: 11563332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular modelling of the differential interaction between several non-steroidal anti-inflammatory drugs and human prostaglandin endoperoxide H synthase-2 (h-PGHS-2).
    Pouplana R; Lozano JJ; Ruiz J
    J Mol Graph Model; 2002 Jan; 20(4):329-43. PubMed ID: 11858641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docking studies on NSAID/COX-2 isozyme complexes using contact statistics analysis.
    Ermondi G; Caron G; Lawrence R; Longo D
    J Comput Aided Mol Des; 2004 Nov; 18(11):683-96. PubMed ID: 15865061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rapid, strong and long-term effectiveness. Coxib also effective in toothache].
    MMW Fortschr Med; 2003 Jan; 145(1-2):53. PubMed ID: 12638443
    [No Abstract]   [Full Text] [Related]  

  • 15. Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.
    Almansa C; Alfón J; de Arriba AF; Cavalcanti FL; Escamilla I; Gómez LA; Miralles A; Soliva R; Bartrolí J; Carceller E; Merlos M; García-Rafanell J
    J Med Chem; 2003 Jul; 46(16):3463-75. PubMed ID: 12877584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel cyclooxygenase-1 inhibitors discovered using affinity fingerprints.
    Hsu N; Cai D; Damodaran K; Gomez RF; Keck JG; Laborde E; Lum RT; Macke TJ; Martin G; Schow SR; Simon RJ; Villar HO; Wick MM; Beroza P
    J Med Chem; 2004 Sep; 47(20):4875-80. PubMed ID: 15369391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analgesic effects of cyclooxygenase 2 inhibitors].
    Jayr C
    Bull Cancer; 2004 May; 91 Spec No():S125-31. PubMed ID: 15239341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Studied on docking of 5,6-diaryl-2,3-dihydro-1-pyrrolizinone derivatives with cyclooxygenase].
    Zhao LQ; Hu YD; Yuan Y; Zhang T; Zhang SF; Li S
    Yao Xue Xue Bao; 2001 Jun; 36(6):415-8. PubMed ID: 12585123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
    Wolfe F; Michaud K; Burke TA; Zhao SZ
    J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse Drug Events Involving COX-2 Inhibitors.
    Verrico MM; Weber RJ; McKaveney TP; Ansani NT; Towers AL
    Ann Pharmacother; 2003 Sep; 37(9):1203-13. PubMed ID: 12921500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.